行情

MYGN

MYGN

万基遗传
NASDAQ

实时行情|Nasdaq Last Sale

34.61
+0.62
+1.81%
交易中 14:17 09/22 EDT
开盘
34.01
昨收
33.99
最高
34.63
最低
33.45
成交量
13.79万
成交额
--
52周最高
36.95
52周最低
11.76
市值
27.01亿
市盈率(TTM)
-22.1175
分时
5日
1月
3月
1年
5年
内幕交易:无数遗传学
MT Newswires · 8小时前
易感性生物标志物市场-预期增长及其因素、复合年增长率、行业规模、业务前景和 2030 年预测
Research Nester published a report titled which delivers detailed overview of the global predisposition biomarkers market in terms of market segmentation by type, application, end-user, and by region.
AmericaNewsHour · 6天前
LabCorp (LH) 通过添加 Myriad's Vectra 支持 RA 测试
Zacks.com · 09/14 14:26
根据 GeneSight® Mental Health Monitor 全国调查显示,只有 8% 的人在抑郁症药物治疗失败后仍抱有希望
SALT LAKE CITY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Depression medication trial and error is far too common – and may result in additional mental health challenges. When people with depression take a medication that does not help them, they reported feeling...
GlobeNewswire · 09/08 20:05
Illumina (ILMN),默克墨水癌症伴随诊断交易
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.
Zacks · 09/08 12:36
Illumina 与默克就癌症突变的诊断测试展开合作
MT Newswires · 09/07 11:26
安捷伦 (A) 促进 PD-L1 IHC 22C3 pharmDX 检测在欧洲的使用
Zacks.com · 08/24 15:44
Tryp Therapeutics 任命 Dennis Langer, MD, JD 为高级顾问
San Diego, California--(Newsfile Corp. - August 18, 2021) - (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointm...
Newsfile Corp · 08/18 11:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解MYGN最新的财务预测,通过MYGN每股收益,每股净资产,每股现金流等数据分析万基遗传近期的经营情况,然后做出明智的投资选择。
分析师评级

9位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测MYGN价格均价为30.25,最高价位42.00,最低价为20.00。
EPS
机构持股
总机构数: 333
机构持股: 8,744.56万
持股比例: 112.03%
总股本: 7,805.54万
类型机构数股数
增持
70
344.02万
建仓
26
252.34万
减持
61
360.34万
平仓
22
78.64万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+1.12%
医疗设备和用品
+1.23%
高管信息
Chairman/Independent Director
S. Louise Phanstiel
President/Chief Executive Officer/Director
Paul Diaz
Chief Financial Officer/Executive Vice President/Treasurer
R. Bryan Riggsbee
Corporate Executive
Melissa Gonzales
Corporate Executive
Nicole Lambert
Corporate Executive
Mark Verratti
Corporate Executive
Faith Zaslavsky
Executive Vice President/General Counsel/Secretary
Benjamin Jackson
Executive Vice President/Director of Human Resources
Jayne Hart
Executive Vice President
Paul Parkinson
Senior Vice President/Chief Marketing Officer
Jeff Borcherding
Senior Vice President
Maggie Ancona
Senior Vice President
Edward Gala
Senior Vice President
David Hammer
Senior Vice President
Chris Williamson
Chief Technology Officer
Kevin Haas
Chief Scientific Officer
Jerry Lanchbury
Vice President
Justin Hunter
Vice President
Karen Renner
Vice President - Business Development
Jackie Zou
Other
Eric Santa
Other
Thomas Slavin
Other
Gwendolyn Turner
Independent Director
Heiner Dreismann
Independent Director
Rashmi Kumar
Independent Director
Dennis Langer
Independent Director
Lee Newcomer
Independent Director
Colleen Reitan
Independent Director
Daniel Skovronsky
Independent Director
Daniel Spiegelman
暂无数据
MYGN 简况
Myriad Genetics, Inc.是一家分子诊断公司。该公司从事发现、开发和销售转化分子诊断测试业务。该公司通过两个业务部门运营:诊断部和其他部。诊断部为评估个人在生命后期发展疾病的风险、识别患者对药物治疗反应的可能性、指导患者的剂量以实现最佳治疗以及评估患者疾病进展和疾病复发的风险提供测试和协作开发测试。其他部为制药、生物技术和医疗研究行业提供测试产品和服务。其他部还为患者提供研发及临床服务。该部门还提供金融、人力资源、法律和信息技术等企业服务。其分子诊断测试包括myRisk Hereditary Cancer、BRACAnalysis CDx和COLARIS。

微牛提供Myriad Genetics, Inc.(NASDAQ-MYGN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MYGN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MYGN股票基本功能。